Eli Lilly

View All

Pharma News and Updates for GSK, BriaCell, Gilead, Lilly, Merck, Halozyme
GSK Acquires Sierra Oncology; BriaCell’s Targeted Breast Cancer Immunotherapy; Merck’s Tepmetko; Gilead’s Magrolimab for MDS and AML; Eli Lilly’s Retevmo; Merck’s Pneumococcal Vaccine; FDA Approves Bevacizumab Biosimilar; Halozyme to Acquire Antares Pharma

GSK Acquires Sierra Oncology for USD 1.9 Billion GlaxoSmithKline has agreed to buy Sierra Oncology and its lead drug assets, momelotinib, for anemia caused by the blood malignancy myelofibrosis. GSK is paying USD 55 per share in cash for Sierra, a 39% premium to the company's closing share price yesterday, valui...

Find More

Intellia's Quest with CRISPR; Innovent, Synaffix ADC Tech Deal; Lilly's Diabetes Blockbuster Tirzepatide; Polyphor’s Bleak Future
Intellia’s Quest with CRISPR; Innovent, Synaffix ADC Tech Deal; Lilly’s Diabetes Blockbuster Tirzepatide; Polyphor’s Bleak Future

A New Dawn for CRISPR, Intellia Edits Cells Inside the Body Intellia Therapeutics, along with its partner Regeneron Pharmaceuticals, recently announced its successful attempt in editing the cells inside the body leveraging the CRISPR technique. The world’s first-ever trial that has their DNA edited through an in...

Find More

recent-pharma-news-and-updates-for-gilead-novartis-lilly-innovent
Novartis’ COVID-19 deal; Shattered hopes for Remdesivir; Lilly’s R&D pact with Precision; Innovent’s Humira Biosimilar

Novartis bags Mesoblast's cell therapy, Remestemcel-L for COVID-19 ARDS The COVID-19 pandemic has put tremendous pressure on scientists to develop a safe and effective vaccine as early as possible. According to the WHO, there are currently more than 100 COVID-19 vaccine candidates under development, with several...

Find More

recent-pharma-news-and-updates-for-az-alkermes-innovent-lillys-avenue
US/AZ deal; Alkermes’ Schizophrenia drug; Innovent/Lilly’s China market expansion; Rejection for Avenue

U.S., AstraZeneca strikes an antibody treatment USD 486 million deal The U.S. government awarded the pharma giant AstraZeneca a sum of USD 486 million for the development of up to 100,000 corona vaccine doses. The deal, under Operation Warp Speed, will people the manufacturing of antibody doses and facilitate th...

Find More

pharma-news
Amylyx Raises $30M; QurAlis Announces License Agreement Deal With Lilly; COVID-19 Vaccine Updates; Researchers Develop a New Ultrafast Insulin

Amylyx Pharmaceuticals grabs USD 30 Million  Amylyx Pharmaceuticals has grabbed USD 30 million boosts after posting positive data, which showed it could help decrease amyotrophic lateral sclerosis (ALS). AMX0035, which is its leading candidate, is being tested in degenerative ALS and Alzheimer’s disease....

Find More

Latest COVID News | Pharma Happenings
HCQ/ CQ failure; AZ/ Catalent’s deal; Sinovac’s CoronaVac and Lilly’s Olumiant trial results

The US FDA nullified the Emergency Use Authorization (EUA) granted to chloroquine phosphate and hydroxychloroquine sulfate to treat COVID-19. The regulatory authority had granted the EUA to malarial drugs to be used in hospitalized COVID-19 patients only when a clinical trial was unavailable, or participation in...

Find More

pharma-news
AbbVie & Genmab’s Collaboration; Lilly’s antisense neuro deal; COVID-19 treatment updates; Roche’s partnership with Innovent;

AbbVie Seals a USD 750 M Bispecific Antibody Cancer Drug Deal with Genmab   AbbVie is set to reimburse Genmab USD 750 million upfront for a stake in a pipeline of anti-cancer bispecifics that is led by epcoritamab. The agreement features up to USD 3.2 billion in milestones, positions AbbVie to race Reg...

Find More

pharma-news
Avrobio taps Magenta’s ADC; Eli Lilly ramps up; FDA postpones decision; CSL gears up to fight pandemic,

Avrobio taps ADC of Magenta for enhancing gene therapy conditioning Avrobio is working to make conditioning safer. The company is collaborating with Magenta Therapeutics to check antibody-drug conjugate. Under the agreement, the partners will evaluate Magenta’s lead conditioning program, MGTA-117, with at lea...

Find More

Non-Small Cell Lung Cancer Market Insights
Novel mutation-targeting therapies in the horizon to relieve the global healthcare burden NSCLC poses

Non-small cell lung cancer market is anticipated to increase in the 7MM from USD 9,730 million in 2017 by 2030. Worldwide, cancer claimed the lives of approximately 9.6 million people in 2018 as per WHO, with lung cancer being the most commonly diagnosed one and accounting for the highest number of deaths (1.76...

Find More

covid-news
In the fight against COVID-19 – Lilly with Olumiant, Gilead with remdesivir, Rutgers with testing kit

Eli Lilly has announced to begin clinical trials of rheumatoid arthritis drug Olumiant to treat COVID-19 patients.  The company plans to explore the anti-inflammatory responses that were witnessed in rheumatoid arthritis patients, and how the drug – Olumiant – an oral JAK1/JAK2 inhibitor – might help in cur...

Find More